Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed by an investigator to have stable plaque psoriasis with no more than 10% body surface area involvement.~* A subject must have an overall baseline score of 6 (moderate) or greater based on a twelve-point scale on the Psoriasis Severity Assessment (PSA) form. Elevation, erythema, and scale will each be graded on a four point scale with a maximum total of 12 points. Each of these 3 variables should be scored as at least a two. (Plaque elevation is defined as the total elevation, including adherent scales, relative to the surrounding skin).~* For female patients of childbearing potential, a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation).~* Negative urine pregnancy test at the time of study entry (for female patients of childbearing potential).~* Written, informed consent and photographic release.~* Ability to follow study instructions and likely to complete all required visits.~Exclusion Criteria:~* A female subject who is pregnant, nursing an infant or planning a pregnancy during the study (throughout the course of the study, women of childbearing potential must use reliable forms of contraception \[i.e., abstinence, spermicides, condoms, or other reliable forms of contraception other than oral contraceptives\].~* A subject with any uncontrolled systemic disease. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.~* A subject with the presence of any skin disease that might interfere with the diagnosis or evaluation of the test medications.~* A subject that has a condition or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.~* A subject with spontaneously improving or rapidly deteriorating plaque psoriasis.~* A subject with pustular or erythrodermic psoriasis.~* A subject diagnosed by an investigator to have stable plaque psoriasis involvement that exceeds more than 10% of the subject's body surface area.~* Use of systemic agents such as oral retinoids, methotrexate, cyclosporine or systemic corticosteroids within four weeks prior to study entry.~* Use of biologic agents such as alefacept, infliximab, efalizumab, adalimumab, or etanercept within four weeks prior to study entry.~* Use of topical drugs that might alter the course of psoriasis (e.g., corticosteroids, retinoids, vitamin D analogues, salicylic acid, tacrolimus, tar and anthralin,) or has received Ultraviolet B treatment within two weeks prior to study entry.~* Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior to study entry.~* A subject with a known sensitivity to any of the study treatments and/or their components.~* A subject who will require excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) during the study.~* A subject who anticipates a need to use other topical or systemic therapy that might alter the course of psoriasis.~* A subject who anticipates the need for surgery or hospitalization during the study.~* Concurrent involvement in any other clinical study with an investigational drug or device, or participation in a clinical study within 30 days prior to entering the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Twice Daily Ultravate (Type: ACTIVE_COMPARATOR): Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
- Once daily Ultravate (Type: ACTIVE_COMPARATOR): Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).